Vitamin D receptor gene polymorphisms and multiple myeloma: a meta-analysis.


Journal

Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405

Informations de publication

Date de publication:
04 Jun 2024
Historique:
received: 19 06 2023
accepted: 18 05 2024
medline: 4 6 2024
pubmed: 4 6 2024
entrez: 4 6 2024
Statut: epublish

Résumé

Vitamin D acts through the vitamin D receptor (VDR), and vitamin D level decreases in multiple myeloma (MM) patients. Single nucleotide polymorphisms in VDR alter its functions to affect the vitamin D status. This raises the question of whether VDR gene polymorphisms are associated with MM risk, which has been investigated in case‒control studies, but the results have been inconsistent. This meta-analysis aimed to investigate the relationship between VDR gene polymorphisms and MM risk. The PubMed, Web of Science, Medline, Embase, Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journal (VIP), Wanfang Databases (WANFANG) were searched from inception to June 1, 2023, without language restriction or publication preference. Pooled odds ratio (OR) and 95% confidence interval (CI) for each variable were calculated. Leave-one-out sensitivity analysis was performed to determine the source of heterogeneity. Publication bias was assessed using Begg' and Egger's tests, and the trim-and-fill method was used to compensate for publication bias. The correlation meta-analysis was conducted using Comprehensive Meta-Analysis 3.0 and STATA 12.0 software. All the included studies were based on Asian populations and involved four VDR gene polymorphisms, TaqI (rs731236), ApaI (rs7975232), BsmI (rs1544410) and FokI (rs2228570). The results showed that TaqI (C vs. T: OR = 1.487, 95% CI 1.052, 2.104, P = 0.025; CC + CT vs. TT: OR = 1.830, 95% CI 1.138, 2.944, P = 0.013), ApaI (T vs. G: OR = 1.292, 95% CI 1.101, 1.517, P = 0.002; TT vs. GG: OR = 1.600, 95% CI 1.106, 2.314, P = 0.013; TG vs. GG: OR 1.305, 95% CI 1.050, 1.622; P = 0.016; TT + TG vs. GG: OR = 1.353, 95% CI 1.103, 1.662, P = 0.004), BsmI (GG vs. AA: OR = 1.918, 95% CI 1.293, 2.844, P = 0.001; GA vs. AA: OR = 1.333, 95% CI 1.058, 1.679, P = 0.015; G vs. A: OR = 1.398, 95% CI 1.180, 1.657, P = 0.000; GG vs. AA + GA: OR = 1.686, 95% CI 1.174, 2.423, P = 0.005), and FokI (T vs. C: OR = 1.687, 95% CI 1.474, 1.931, P = 0.000; TT vs. CC: OR = 2.829, 95% CI 2.066, 3.872, P = 0.000; TC vs. CC: OR = 1.579, 95% CI 1.304, 1.913, P = 0.000, TT + TC vs. CC: OR = 1.771, 95% CI 1.477, 2.125, P = 0.000; TT vs. CC + TC: OR = 2.409, 95% CI 1.814, 3.200, P = 0.000) are associated with MM risk. VDR gene polymorphisms including ApaI, BsmI, TaqI, and FokI are associated with MM risk in Asian populations. Additional studies with large sample sizes and different ethnicities are needed.

Identifiants

pubmed: 38833040
doi: 10.1007/s10238-024-01382-4
pii: 10.1007/s10238-024-01382-4
doi:

Substances chimiques

Receptors, Calcitriol 0
VDR protein, human 0

Types de publication

Meta-Analysis Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

118

Subventions

Organisme : Natural Science Foundation of Shandong Province
ID : ZR2020KH023

Informations de copyright

© 2024. The Author(s).

Références

Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962–72. https://doi.org/10.1182/blood-2007-10-078022 .
doi: 10.1182/blood-2007-10-078022 pubmed: 18332230 pmcid: 2265446
Ismail NH, Mussa A, Al-Khreisat MJ, Yusoff SM, Husin A, Johan MF, et al. The global prevalence of vitamin D deficiency and insufficiency in patients with multiple myeloma: a systematic review and meta-analysis. Nutrients. 2023. https://doi.org/10.3390/nu15143227 .
doi: 10.3390/nu15143227 pubmed: 38068713 pmcid: 10708020
Mirhosseini N, Psihogios A, McLaren MD, Seely D. Vitamin D and multiple myeloma: a scoping review. Curr Oncol. 2023;30(3):3263–76. https://doi.org/10.3390/curroncol30030248 .
doi: 10.3390/curroncol30030248 pubmed: 36975461 pmcid: 10047650
Puthier D, Bataille R, Barille S, Mellerin M-P, Harousseau J-L, Ponzio A, et al. High prevalence of peripheral neuropathy in multiple myeloma patients and the impact of vitamin D levels, a cross-sectional study. Support Care Cancer. 2021;30(1):271–8. https://doi.org/10.1007/s00520-021-06414-3 .
doi: 10.1007/s00520-021-06414-3
Wang J, Udd KA, Vidisheva A, Swift RA, Spektor TM, Bravin E, et al. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Support Care Cancer. 2016. https://doi.org/10.1007/s00520-016-3126-1 .
doi: 10.1007/s00520-016-3126-1 pubmed: 28039504 pmcid: 5266776
Yellapragada SV, Fillmore NR, Frolov A, Zhou Y, Dev P, Yameen H, et al. Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. Blood Adv. 2020;4(8):1643–6. https://doi.org/10.1182/bloodadvances.2019001411 .
doi: 10.1182/bloodadvances.2019001411 pubmed: 32315398 pmcid: 7189302
Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, et al. Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol. 2000;109(3):576–83. https://doi.org/10.1046/j.1365-2141.2000.02046.x .
doi: 10.1046/j.1365-2141.2000.02046.x pubmed: 10886207
Park WH, Seol JG, Kim ES, Binderup L, Koeffler HP, Kim BK, et al. The induction of apoptosis by a combined 1,25(OH)2D3 analog, EB1089 and TGF-beta1 in NCI-H929 multiple myeloma cells. Int J Oncol. 2002;20(3):533–42.
pubmed: 11836565
Puthier D, Bataille R, Barille S, Mellerin M-P, Harousseau J-L, Ponzio A, et al. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Blood. 1996;88(12):4659–66. https://doi.org/10.1182/blood.V88.12.4659.bloodjournal88124659 .
doi: 10.1182/blood.V88.12.4659.bloodjournal88124659 pubmed: 8977259
Park WH, Seol JG, Kim ES, Jung CW, Lee CC, Binderup L, et al. Cell cycle arrest induced by the vitamin D(3) analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27. Exp Cell Res. 2000;254(2):279–86. https://doi.org/10.1006/excr.1999.4735 .
doi: 10.1006/excr.1999.4735 pubmed: 10640426
Kumagai T, O’Kelly J, Said JW, Koeffler HP. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst. 2003;95(12):896–905. https://doi.org/10.1093/jnci/95.12.896 .
doi: 10.1093/jnci/95.12.896 pubmed: 12813173
Cavalier E, Makris K, Heijboer AC, Herrmann M, Souberbiellee J-C. Vitamin D: analytical advances, clinical impact, and ongoing debates on health perspectives. Clin Chem. 2024. https://doi.org/10.1093/clinchem/hvae056 .
doi: 10.1093/clinchem/hvae056 pubmed: 38825342
Zhang R, Naughton DP. Vitamin D in health and disease: current perspectives. Nutr J. 2010;9(1):66. https://doi.org/10.1186/1475-2891-9-65 .
doi: 10.1186/1475-2891-9-65
Bouillon R, Carmeliet G, Verlinden L, Etten Ev, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29(6):726–76. https://doi.org/10.1210/er.2008-0004 .
doi: 10.1210/er.2008-0004 pubmed: 18694980 pmcid: 2583388
Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001;177(1–2):145–59. https://doi.org/10.1016/s0303-7207(01)00406-3 .
doi: 10.1016/s0303-7207(01)00406-3 pubmed: 11377830
Vaughan-Shaw PG, O’Sullivan F, Farrington SM, Theodoratou E, Campbell H, Dunlop MG, et al. The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis. Br J Cancer. 2017;116(8):1092–110. https://doi.org/10.1038/bjc.2017.44 .
doi: 10.1038/bjc.2017.44 pubmed: 28301870 pmcid: 5396104
Sergentanis TN, Zagouri F, Tsilimidos G, Tsagianni A, Tseliou M, Dimopoulos MA, et al. Risk factors for multiple myeloma: a systematic review of meta-analyses. Clin Lymphoma Myeloma Leuk. 2015;15(10):563-77.e773. https://doi.org/10.1016/j.clml.2015.06.003 .
doi: 10.1016/j.clml.2015.06.003 pubmed: 26294217
Gnagnarella P, Raimondi S, Aristarco V, Johansson H, Bellerba F, Corso F, et al. Ethnicity as modifier of risk for Vitamin D receptors polymorphisms: comprehensive meta-analysis of all cancer sites. Crit Rev Oncol Hematol. 2021;158: 103202. https://doi.org/10.1016/j.critrevonc.2020.103202 .
doi: 10.1016/j.critrevonc.2020.103202 pubmed: 33387627
He Y, Ou C, Pang W, Lin Y, He J, Li C, et al. Genetic association of VDR polymorphisms and multiple myeloma susceptibility: a case control study. Int J Clin Exp Pathol. 2017;10(3):3538–42.
Chen P, Du Z-L, Zhang Y, Liu B, Guo Z, Lou J-X, et al. Association of VEGF and VDR gene–gene and gene-smoking interaction on risk of multiple myeloma in Chinese Han population. Oncotarget. 2017;8(22):36509–16. https://doi.org/10.18632/oncotarget.16510 .
doi: 10.18632/oncotarget.16510 pubmed: 28380424 pmcid: 5482672
Ni Z, Vitamin D. Receptor gene polymorphism and it’s association with multiple myeloma. People’s Hospital of Xinjiang Uygur Autonomous Region. Urumqi: Xinjiang Medical University; 2020.
Kumar R, Himani A, Gupta N, Singh V, Kumar V, Haq A, et al. Unveiling molecular associations of polymorphic variants of VDR gene (FokI, BsmI and ApaI) in multiple myeloma patients of Indian population. J Steroid Biochem Mol Biol. 2020. https://doi.org/10.1016/j.jsbmb.2020.105588 .
doi: 10.1016/j.jsbmb.2020.105588 pubmed: 32004705
Rui H, Liu Y, Lin M, Zheng X. Vitamin D receptor gene polymorphism is associated with multiple myeloma. J Cell Biochem. 2020;121(1):224–30. https://doi.org/10.1002/jcb.29135 .
doi: 10.1002/jcb.29135 pubmed: 31172589
Shafia S, Qasim I, Aziz SA, Bhat IA, Nisar S, Shah ZA. Role of vitamin D receptor (VDR) polymorphisms in susceptibility to multiple myeloma in ethnic Kashmiri population. Blood Cells Mol Dis. 2013;51(1):56–60. https://doi.org/10.1016/j.bcmd.2013.02.001 .
doi: 10.1016/j.bcmd.2013.02.001 pubmed: 23453529
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71 .
doi: 10.1136/bmj.n71 pubmed: 33782057 pmcid: 8005924
Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7(1):16. https://doi.org/10.1186/1472-6947-7-16 .
doi: 10.1186/1472-6947-7-16 pubmed: 17573961 pmcid: 1904193
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis; 2012. Accessed 2012.
Zhang R, Zhang Y, Liu Z, Pei Y, Xu P, Chong W, et al. Association betweeN vitamin D supplementation and cancer mortality: a systematic review and meta-analysis. Cancers. 2022;14(15):66. https://doi.org/10.3390/cancers14153717 .
doi: 10.3390/cancers14153717
Jeon S-M, Shin E-A. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018;50(4):1–14. https://doi.org/10.1038/s12276-018-0038-9 .
doi: 10.1038/s12276-018-0038-9 pubmed: 30333528
Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, et al. Prediction of bone density from vitamin D receptor alleles. Nature. 1994;367(6460):284–7.
doi: 10.1038/367284a0 pubmed: 8161378
Martelli FS, Mengoni A, Martelli M, Rosati C, Fanti E. VDR TaqI polymorphism is associated with chronic periodontitis in Italian population. Arch Oral Biol. 2011;56(12):1494–8. https://doi.org/10.1016/j.archoralbio.2011.06.012 .
doi: 10.1016/j.archoralbio.2011.06.012 pubmed: 21764034
Castillo-Avila RG, González-Castro TB, Tovilla-Zárate CA, Juárez-Rojop IE, López-Narváez ML, Rodríguez-Pérez JM, et al. The role of TaqI, ApaI and BsmI polymorphisms of VDR gene in lumbar spine pathologies: systematic review and meta-analysis. Eur Spine J. 2021;30(7):2049–59. https://doi.org/10.1007/s00586-021-06872-7 .
doi: 10.1007/s00586-021-06872-7 pubmed: 34021784
Cong L, Wang W, Liu Q, Du J. FokI polymorphism of the vitamin D receptor gene is associated with susceptibility to gastric cancer: a case–control study. Tohoku J Exp Med. 2015;236(3):219–24. https://doi.org/10.1620/tjem.236.219 .
doi: 10.1620/tjem.236.219 pubmed: 26105695

Auteurs

Chunyi Lyu (C)

Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.

Xuewei Yin (X)

Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.

Zonghong Li (Z)

Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.

Teng Wang (T)

Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.

Ruirong Xu (R)

Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China. shandongxuruirong@163.com.
Shandong Key Laboratory of Hematology of Integrated Traditional Chinese and Western Medicine of Health Commission, Institute of Hematology, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China. shandongxuruirong@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH